EAU 2022: Metastatic Prostate Cancer: The Role of PSMA Radioligand Treatment in Castrate Resistant M1 Prostate Cancer
EAU 2022 modern diagnostic and therapeutic approaches in prostate cancer, the role of PSMA radioligand treatment in castrate-resistant M1 prostate cancer.